Clinical Trial Update: Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial updating on lapatinib for persistent or recurrent ovarian epithelial or peritoneal cancer has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Epithelial Cancer
• Peritoneal Cavity Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-06-11